Albiglutide is an agonist of the GLP-1 receptor and augments glucose-dependent insulin secretion. Albiglutide also slows gastric emptying.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
Albiglutide is the active ingredient of these drugs:
Estonia Lithuania